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Urgent reperfusion of the ischaemic brain is the aim of stroke treatment and there has been ongoing research to find a drug
that can promote vessel recanalisation more completely and with less side effects. In this review article, the major studies which
have validated the use and safety of tPA are discussed. The safety and efficacy of other thrombolytic and anticoagulative agents
such as tenecteplase, desmoteplase, ancrod, tirofiban, abciximab, eptifibatide, and argatroban are also reviewed. Tenecteplase and
desmoteplase are both plasminogen activatorswith higher fibrin affinity and longer half-life compared to alteplase.They have shown
greater reperfusion rates and improved functional outcomes in preliminary studies. Argatroban is a direct thrombin inhibitor used
as an adjunct to intravenous tPA and showed higher rates of complete recanalisation in the ARTTS study with further studies
which are now ongoing. Adjuvant thrombolysis techniques using transcranial ultrasound are also being investigated and have
shown higher rates of complete recanalisation, for example, in the CLOTBUST study. Overall, development in medical therapies
for stroke is important due to the ease of administration compared to endovascular treatments, and the new treatments such as
tenecteplase, desmoteplase, and adjuvant sonothrombolysis are showing promising results and await further large-scale clinical
trials.
1. Introduction
Stroke is a major public health problem worldwide and
is considered the third most costly health condition in
developed countries [1]. Approximately 800,000 strokes are
reported in the United States every year leading to 200,000
deaths, almost 1 out of every 16 deaths [2, 3]. For those
who survive, it is the most common cause of adult disability
in the modern world and associated with expensive long-
term rehabilitation care [2, 4–6]. Costs are estimated over
60 billion dollars per year in the United States alone [2, 4,
7]. More than 80% of stroke victims suffer from a disease
ischemic in nature due to a thrombus or thromboembolism,
with the remainder haemorrhagic [2].
During stroke, a core area of tissue dies due to underper-
fusion and an area of hypoperfused tissue with some collat-
eral vessels remains salvageable (penumbra) if revascularised
in a timely manner [8]. The NIHSS (National Institute of
Health Stroke Score) is a quick tool to clinically estimate the
extent and the severity of it. The score is shown in Table 1.
Urgent reperfusion of the ischaemic brain remains the
first target of stroke treatment, either by intravenous medical
therapy or by endovascular intervention. Restoration of
blood flow to ischaemic tissue has been shown to improve
functional outcome and decrease mortality at 3 months
compared to no revascularization [9]. Indeed studies have
estimated 1.8 days of added healthy life benefit for each
minute reduction in time to treatment [10]. An Australian
study found that 69% of patients with acute ischaemic stroke
were not eligible for thrombolysis due to delay in presentation
[11]. Currently intravenous recombinant tissue plasminogen
activator (tPA) is only recommended to be used within
the 4.5-hour window beyond which the risk of intracranial
bleeding may outweigh the benefits [12]. Implementation of
stroke systems of care as well as specialisedmobile stoke units
has proven to reduce the mean time to treatment [13].
Intravenous tPA has been widely accepted as the first-
line drug of choice for thrombolysis since FDA approval in
1996 [14]. However, the short therapeutic window, risk of
Hindawi Publishing Corporation
rombosis
Volume 2014, Article ID 714218, 14 pages
http://dx.doi.org/10.1155/2014/714218
2 Thrombosis
Table 1: National Institutes of Health Stroke Scale.
Tested item Title Response and score
1A Level of consciousness
0 = alert
1 = drowsy
2 = obtunded
3 = coma/unresponsive
1B Orientation questions (2)
0 = answers both correctly
1 = answers one correctly
2 = answers neither correctly
1C Response to commands (2)
0 = performs both tasks correctly
1 = performs one task correctly
2 = performs neither
2 Gaze
0 = normal horizontal movements
1 = partial gaze palsy
2 = complete gaze palsy
3 Visual fields
0 = no visual field defect
1 = partial hemianopia
2 = complete hemianopia
3 = bilateral hemianopia
4 Facial movement
0 = normal
1 = minor facial weakness
2 = partial facial weakness
3 = complete unilateral palsy
5
Motor function (arm)
(a) Left
(b) Right
0 = no drift
1 = drift before 5 seconds
2 = falls before 10 seconds
3 = no effort against gravity
4 = no movement
6
Motor function (leg)
(a) Left
(b) Right
0 = no drift
1 = drift before 5 seconds
2 = falls before 5 seconds
3 = no effort against gravity
4 = no movement
7 Limb ataxia
0 = no ataxia
1 = ataxia in 1 limb
2 = ataxia in 2 limbs
8 Sensory
0 = no sensory loss
1 = mild sensory loss
2 = severe sensory loss
9 Language
0 = normal
1 = mild aphasia
2 = severe aphasia
3 = mute or global aphasia
0 = normal
10 Articulation 1 = mild dysarthria
2 = severe dysarthria
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Table 1: Continued.
Tested item Title Response and score
11 Extinction or inattention
0 = absent
1 = mild (loss 1 sensory modality)
2 = severe (loss 2 modalities)
Adapted from Adams et al. (2007) [15].
intracranial haemorrhage, and limited efficacy at recanalisa-
tion of large vessel occlusion have spurred the development of
endovascular treatments as well as other thrombolytic agents
which have higher fibrin affinity and better safety profile.
This paper is part of a two-part review on advances in
stroke treatment andwill focus onmedical treatment over the
past decade and discuss the implications for future research
and treatment.
2. Intravenous Thrombolysis
2.1. Tissue Plasminogen Activator (tPA). Despite enormous
advancement in the therapeutic options available, the stan-
dard treatment for an ischemic stroke is still intravenous
thrombolysis following a noncontrast CT brain. Intravenous
tPA is administered at a dose of 0.9mg/kg, with a maximum
dose of 90mg. Ten percent of the medication is given as a
bolus and the remainder is infused over 60minutes [2, 34, 35].
Intravenous tPA therapy in the first 3 hours after stroke onset
was demonstrated to be beneficial in the NINDS (National
Institute of Neurological Disorders and Stroke) study, which
reported a significantly greater proportion of patients having
a normal or near normal outcome compared to placebo (38
versus 21 percent, 𝑃 = 0.001) [16].
In 2009, the ECASS 3 study (EuropeanCooperative Acute
Stroke Study 3) demonstrated that patients treated with
intravenous tPA in the 3–4.5-hour window showed improved
outcome compared to placebo (mRS 0-1 in 52 versus 45
percent, 𝑃 = 0.04) with no increase in mortality [17].This led
to the American Heart Association (AHA/ASA) guidelines
for intravenous tPA administration to be revised to increase
the window of treatment from 3 hours to 4.5 hours given
certain limitations and patient-specific criteria (patients with
age >80, NIHSS > 25, previous stroke and diabetes, and
anticoagulant use were excluded) [1, 34, 36].
The effectiveness of intravenous tPA for use between 4.5
and 6 hours after stroke onset is inconclusive. The results of
the IST-3 trial which enrolled 3035 patients within 6 hours of
stroke onset showed a greater rate of symptomatic intracra-
nial haemorrhage and mortality, but only insignificant trend
towards favourable outcome at 6 months in IV tPA versus
control group, 37 versus 35 percent (𝑃 = 0.181) [18]. The
results of the large Ischemic Stroke Recorded in the Safe
Implementation (SITS-IST) registry on 29,619 patients did
not show worse outcome in patients treated within 4.5 to 6
hours of stroke compared to patients treated within 4.5 or 3
hours [19].
Researchers have also investigated the combination of
intravenous tPA and heparin or antiplatelet therapy to
prevent reocclusion of vessels. Although not statistically
significant, a trend towards more favourable outcome in
patients treated with intravenous tPA combined with low
molecular weight heparin at presentation was shown. This
was associated with a small increased risk of symptomatic
intracranial haemorrhage [37, 38]. The Antiplatelet Therapy
in Combination with Recombinant tPA Thrombolysis in
Ischemic Stroke (ARTIS) study showed that use of 300mg
intravenous acetyl salicylic acid within 1.5 hours of tPA
did not improve outcome at 3 months and increased the
rate of symptomatic intracranial haemorrhage [20, 37, 39].
Consistent with current guidelines, there is no evidence to
support initiation of antiplatelet within the first 24 hours after
tPA is administered.
2.2. Other Thrombolytic Agents. Conventional thrombolytic
agents like alteplase (recombinant tPA) and prourokinase
work by converting plasminogen into active plasmin [2,
17, 40, 41]. Although alteplase is the only FDA approved
treatment for acute ischemic stroke, newer agents are emerg-
ing with the goal to improve the risk-benefit profile of
thrombolysis.There are also concerns that alteplasemay have
negative effects on the ischaemic brain, including cytotox-
icity and increased permeability of the blood-brain-barrier
(BBB) facilitating cerebral oedema [42]. Efficacy of new
agents like tenecteplase, reteplase, plasmin, microplasmin,
and desmoteplase and their combination therapy is now
being investigated [2, 36, 37, 43].
2.3. Tenecteplase. Tenecteplase is a semisynthetic tPA struc-
turally modified to have increased half-life and fibrin affinity
and has shown promise in the treatment of ischemic stroke
[37, 39, 44]. Parsons et al. (2012) randomised 75 patients
to receive alteplase (0.9mg per kilogram of body weight)
or tenecteplase (0.1mg per kilogram or 0.25mg per kilo-
gram) and showed that the two tenecteplase groups had
greater reperfusion compared to alteplase and the high dose
tenecteplase group was superior to the lower dose group in
all outcome measures [21].
Smadja et al. (2011) investigated the efficacy of 0.1mg per
kilogram intravenous bolus of tenecteplase as an adjuvant in
MCA (M1) occlusions not responsive to intravenous tPA. Out
of the 13 patients treated, the recanalisation (TIMI 2/3) rate
was 100% and modified Rankin Scale (mRS) 0-1 achieved in
69% of patients at 90 days [45].
Further studies are ongoing, including The Norwegian
Tenecteplase Stroke Trial (NOR-TEST) which is a ran-
domised controlled trial comparing efficacy and safety of
tenecteplase versus alteplase in stroke patients who present
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within 4.5 hours of stroke onset as well as comparing them as
bridging therapy prior to embolectomy [46].
2.4. Desmoteplase. Desmoteplase is a plasminogen activator
extracted from the vampire bat saliva, with higher fibrin
affinity compared with tPA and long half-life, making it a
promising thrombolytic agent. The Desmoteplase in Acute
Stroke (DIAS) study investigated the safety and efficacy of
various doses of intravenous desmoteplase in patients with
perfusion-diffusion mismatch on MRI up to 3 hours from
stroke onset. Part 1 of the trial was terminated prematurely
due to high rates of symptomatic intracranial haemorrhage
(up to 30%) but the second part with lower weight adjusted
desmoteplase doses showed increased reperfusion and better
functional outcomes in the desmoteplase group compared to
placebo [22, 37].
DIAS was followed by the phase II placebo-controlled
Dose Escalation of Desmoteplase for Acute Ischemic Stroke
(DEDAS) study, which demonstrated safety and efficacy
of 125 𝜇g per kilogram dose of intravenous desmoteplase
in acute ischemic stroke, although only 25 patients were
included in the treatment groups [14, 37].
The subsequent small phase III study, DIAS-2, did not
show a benefit of desmoteplase over placebo. This could
be explained by a number of factors including the milder
stroke severity scores of patients in the study, small core, and
mismatch lesion volumes and only 30% of patients in the
study had proximal vessel occlusion [4, 37]. Further studies
are warranted and phase III DIAS-3 and DIAS-4 trials are
now ongoing to evaluate safety and efficacy of 90 ug per
kilogram bolus given 3–9 hours after stroke onset [47].
2.5. Ancrod. Ancrod is a serine protease, extracted from
the venom of the Malayan pit viper that reduces blood
fibrinogen levels when injected intravenously. This indi-
rectly leads to anticoagulation, reduced blood viscosity, and
increased circulation to affected areas of the brain [48]. It
was initially shown to be beneficial in acute ischemic stroke
if started within 3 hours of symptom onset [23, 37, 49].
The Stroke Treatment with Ancrod Trial (STAT) randomised
500 patients who presented within 3 hours of stroke onset
to receive an infusion of ancrod or placebo over 72 hours
and 1-hour infusions at 96 and 120 hours. Better functional
outcome was observed in the ancrod group versus placebo,
42.2% versus 34.4%, with a 𝑃 value of 0.04. However the rate
of symptomatic intracranial haemorrhage was insignificantly
greater in the ancrod group, 5.2% versus 2%, 𝑃 value of 0.06
[23]. Subsequent studies extending the treatment window to
6 hours from onset have not been able to demonstrate any
significant difference in clinical outcome [37, 49–51].
2.6. Glycoprotein IIb/IIIa Antagonists. Glycoprotein IIb/IIIa
inhibitors may prevent platelet activation thus preventing
reocclusion as well as facilitating more complete and faster
thrombus breakdown [52].They have been shown as an adju-
vant to improve coronary recanalisation in acute myocardial
infarction with more TIMI 3 reperfusion in phase II studies
but no significant final outcome improvement in the phase III
study [37, 53, 54].
Safety of Tirofiban in Acute Ischemic Stroke (SaTIS) is
a phase II placebo-controlled study on monotherapy with
intravenous tirofiban in patients presenting up to 22 hours
after onset. The study confirmed its safety; however there
was no neurological/functional benefit found compared with
placebo at 5 months except for lower mortality shown in
the treatment group [24, 37]. The subsequent Abciximab
in Emergency Treatment of Stroke Trial (AbESTT-II), an
attempt for a phase III study on GP IIb/IIIa inhibitor
monotherapy, was terminated prematurely because of an
unfavourable risk-benefit profile. No benefit in neurological
recovery was seen in any of the cohorts (within 5-hour onset,
between 5-6 hours and wake-up strokes) in the abciximab
group compared to placebo. Instead, there was a signifi-
cant increase in symptomatic intracranial haemorrhage. The
authors conclude that intravenous abciximab does not have
a role in the management of patients with acute ischaemic
stroke [25, 37, 55].
Efficacy and safety of combined intravenous tPA and
eptifibatide comparedwith intravenous tPA alonewere inves-
tigated in the phase II Combined Approach to Lysis Utilizing
Eptifibatide and Recombinant Tissue Plasminogen Activator
in Acute Ischemic Stroke—Enhanced Regimen stroke trial
(CLEAR-ER) study. The combined treatment group had a
lower rate of symptomatic intracranial haemorrhage (2%)
and showed a trend towards better functional outcome, with
49.5% achieving mRS 0-1 versus 36% in the standard tPA
group [26].
2.7. Argatroban. Argatroban is a direct thrombin inhibitor
which has demonstrated safety in the Argatroban Antico-
agulation in Patients with Acute Ischemic Stroke (ARGIS-
I) trial. Patients were randomised to receive a high or low
dose intravenous infusion of argatroban or placebo within 12
hours of stroke onset. The rate of symptomatic haemorrhage
was nonsignificantly higher in the argatroban groups (5% and
3% versus 0% in placebo); however, the argatroban groups
did not show any benefit in functional outcome compared
to placebo. Use of argatroban as an adjuvant to intravenous
tPA was investigated in the Argatroban TPA Stroke (ARTTS)
study and showed 63% complete recanalisation rate at 24
hours [27, 28, 32, 37, 56–59]. Phase II ARTTS-2 (Randomized
Controlled Trial of Argatroban with tPA for Acute Stroke) is
currently recruiting patients randomised to receive a high or
low dose of argatroban infusion for 48 hours and intravenous
tPA versus tPA alone and is expected to be completed in 2015
[60].
These important trials have been summarized in Table 2.
3. Factors Affecting Outcome of Thrombolysis
As mentioned before, restoration of cerebral blood flow to
ischaemic brain tissue with clot lysis and recanalisation is
the immediate aim of thrombolytic therapy. A meta-analysis
on 2006 patients showed that recanalisation compared to no
recanalisation was associated with good functional outcome
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(OR 4.43, 95% CI 3.32–5.91) and reduced mortality (OR
0.24, 95% CI 0.16–0.35) at 3 months [9]. The outcome of
thrombolysis in ischemic stroke depends on multiple factors
including thrombus type, location and the extent, collateral
circulation, underlying comorbidities, patient’s age, time to
commencement of the treatment, and time to recanalisation
[2].
Studies have shown that large calibre proximal arteries are
unlikely to be responsive to chemical intravenous thromboly-
sis alone [37, 61, 62]. On transcranial ultrasound study, intra-
venous thrombolysis showed recanalisation rates of 44.2% for
distal middle cerebral artery (M2) occlusion, which drops
significantly to 30% and 6% for proximal MCA (M1) and
distal ICA, respectively [37, 62]. While studies report wide
variation in recanalisation rates for large proximal cerebral
artery occlusions with intravenous thrombolysis alone, even
the highest rates support the fact that there is room for
improvement [63].
Clinical trials have also shown that the likelihood of
recanalisation negatively correlates with the thrombus bur-
den, with those having a clot less than 8mm in length having
a much better chance to achieve recanalisation [2, 64].
Clot composition may also determine effectiveness of
thrombolysis. A study found that fibrin rich cardioembolic
thrombus achieved faster and more frequent recanalisation
with tPA compared to large vessel atherosclerotic lesions [63].
In a case series with complete or partial MCA recanalisation
after intravenous tPA, 20% of patients had early reocclusion
and risk factors for this include NIHSS score more than 16 at
baseline and severe ipsilateral carotid artery disease, which is
defined as more than 70% stenosis in this study [65].
MRI/CT perfusion imaging studies in acute stroke are
showing promise to provide a basis to select patients with
salvageable brain that will do well past the traditional 3- to
4.5-hour treatment window as well as selection of patients
who present with wake-up stroke. This is investigated in
the Diffusion and Perfusion Imaging Evaluation for Under-
standing Stroke Evaluation (DEFUSE) study andMRI Profile
and Response to Endovascular Reperfusion after Stroke
(DEFUSE-2) study. Both studies showed that perfusion mis-
matched patients who had early reperfusion after tPA or
endovascular stroke treatment had more favourable clinical
outcomes and attenuation of infarct growth. The studies also
highlighted a subset of patients with a “malignant mismatch”
profile characterised by large DWI, more than 100mL, who
were more likely to have serious intracranial haemorrhage
and poor outcome after reperfusion [29, 30].
The effects of alteplase beyond 3 hours after stroke
in the Echoplanar Imaging Thrombolytic Evaluation Trial
(EPITHET) is a randomised controlled trial looking at
intravenous tPA versus placebo in patients with a perfusion
mismatch 3 to 6 hours after stoke onset. Compared to placebo,
intravenous tPA was nonsignificantly associated with better
clinical outcome at 90 days but significantly associated with
higher rates of reperfusion, 56% versus 26%, with a 𝑃 value of
0.01. The study also found a significant association between
overall reperfusion with better clinical outcome and less
infarct growth [31]. Further randomised controlled trials are
now underway to assess if patients with significant penumbra
mismatch at 3 to 9 hours from onset would benefit from tPA
(EXTEND study) [66].
WAKE-UP is another ongoing randomised controlled
trial that uses DWI-FLAIR mismatch to identify patients for
intravenous thrombolysis with tPA amongst patients who
wake up with stroke symptoms [67].
4. Other Emerging Treatments
4.1. Sonothrombolysis. The Combined Lysis Of Thrombus in
Brain Ischemia Using Transcranial Ultrasound and Systemic
tPA (CLOTBUST) study showed that the thrombolytic effi-
cacy of intravenous tPA was increased, presumably due to
the separating effect of energy delivered by sound waves on
fibrin strands in the thrombus [32, 37, 68]. Although no
significant improvement in clinical outcome was detected
(study was not powered for clinical outcome) it was shown
that transcranial emission of a 2MHz sound beam for 2
hours, targeted towards the thrombus and proximal MCA,
significantly increased the rate of complete recanalisation
with tPA compared with placebo (38% versus 13%) with no
increase in complications or risk of haemorrhage [32, 37, 68].
Studies using lower frequency beams for better mechanical
advantage were shown to be unsafe [37, 69].
Phase III randomised study CLOTBUST-ER is ongoing
and evaluates the efficacy and safety of the Clotbust-ER
ultrasound (ultrasonic headframe) device when used in
combination with standard intravenous tPA. The study has
completed enrolment of half the subjects (460 of 800)without
being halted on interim analysis. Primary efficacy endpoint
is 90-day functional recovery and incidence of symptomatic
intracranial haemorrhage (sICH) as the primary safety end-
point [70].
Ultrasound contrast agents have showed that further
energy can be delivered to the tissue when oscillating
microbubbles cavitate, facilitating thrombus degradation and
likely promoting recanalization [37]. The Transcranial Ultra-
Sound in Clinical SoNo-Thrombolysis (TUSCAN) study
looked into the safety and efficacy of ultrasound assisted
tPA thrombolysis, using escalating doses of lipid-based
microbubbles (Microsphere), which are resistant to transpul-
monary passage. The study demonstrated 67% complete
recanalisation following the first dose [33, 37]. However,
the study was terminated prematurely due to significantly
increased risk of intracranial haemorrhage after the second
dose [33, 37].
In another study, three different groups of stroke patients
within 3 hours received tPA alone, tPA and ultrasound,
and combined tPA, ultrasound, and microbubbles. The final
comparison demonstrated safety of themicrobubbles with no
increased treatment complications and significantly higher
recanalisation rate [37, 71], warranting further comprehen-
sive studies into efficacy of sonothrombolysis [17, 69].
5. Conclusion
This paper highlights the evidence for intravenous tPA
thrombolysis and newer adjuvant therapies. The common
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goal in chemical or mechanical recanalisation is to establish
flow to the ischaemic areas of the brain.There is clearly a role
for thrombolysis in the acutemanagement of stroke care since
it is easily accessible in primary stroke centres and does not
require a catheter lab.
There is an ongoing search for thrombolytic agents
that are more effective than tPA and can be used safely
over a longer period to maximise the benefit to a greater
number of patients. Tenecteplase is one such agent that
has shown promising results. Adjuvant antithrombotics such
as argatroban have shown high recanalisation rates with
intravenous tPA in a single arm study and await confirmation
of superiority in an ongoing randomised trial. Adjuvant
use of transcranial ultrasound has been shown to improve
recanalisation rateswith intravenous tPA in phase II trials and
is now undergoing phase III testing.The use of neuroimaging
to provide more robust selection criteria to delineating
patients with perfusion mismatch is a key focus of research,
with ongoing phase III trials.
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